Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Day: March 10, 2026

Endocrinology

Endocrinology Today—March 10, 2026

This week’s Endocrinology update highlights regulatory progress in osteoporosis…

Obesity Weekly News

Obesity Today—March 10, 2026

This week’s Obesity update highlights regulatory approvals, emerging generic…

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: kyron.bio x Servier strategic partnership

Lucid Diligence Brief: kyron.bio x Servier strategic partnership Professional…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Neuroscience Today—April 1, 2026
Immunology Today—April 1, 2026
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Women’s Health Today—April 1, 2026
ACC 2026 Preview: Key Cardiology Highlights to Watch

Tags

AI-native clinical development Alphamab Oncology AMXT 1501 Charles River Chronic disease mortality Clemann Group conduction-system pacing cost reduction CUF DA-1726 dialysis DIPS Arena Eledon Pharmaceuticals Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Glanzmann Thrombasthenia GLP-1 Receptor Agonists GNTI-122 gout flares HMPL-760 Jaypirca live biotherapeutic product Lonza MicroRNAs naxtarubicin OCALIVA oral therapeutics PPMS psychiatry QRX003 ralinepag Receptor.AI Rinvoq Rituximab Romeck Pharma Spikevax Stanford Medicine Sutra Medical TG Therapeutics TLR4 Transgene Ver-A-T1D

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Neuroscience Today—April 1, 2026
Immunology Today—April 1, 2026
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Women’s Health Today—April 1, 2026
ACC 2026 Preview: Key Cardiology Highlights to Watch

TAGS

AI-native clinical development Alphamab Oncology AMXT 1501 Charles River Chronic disease mortality Clemann Group conduction-system pacing cost reduction CUF DA-1726 dialysis DIPS Arena Eledon Pharmaceuticals Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Glanzmann Thrombasthenia GLP-1 Receptor Agonists GNTI-122 gout flares HMPL-760 Jaypirca live biotherapeutic product Lonza MicroRNAs naxtarubicin OCALIVA oral therapeutics PPMS psychiatry QRX003 ralinepag Receptor.AI Rinvoq Rituximab Romeck Pharma Spikevax Stanford Medicine Sutra Medical TG Therapeutics TLR4 Transgene Ver-A-T1D

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy